$0.70
10.84% today
Nasdaq, Apr 04, 09:28 pm CET
ISIN
US48669G1058
Symbol
KZIA
Sector
Industry

Kazia Therapeutics Ltd Sponsored ADR Stock price

$0.79
-0.03 3.29% 1M
-3.50 81.68% 6M
-0.98 55.64% YTD
-2.58 76.69% 1Y
-80.91 99.04% 3Y
-25.71 97.04% 5Y
-166.00 99.53% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.01 1.85%
ISIN
US48669G1058
Symbol
KZIA
Sector
Industry

Key metrics

Market capitalization $2.61m
Enterprise Value $1.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.26
P/S ratio (TTM) P/S ratio 1.72
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $1.52m
EBIT (operating result TTM) EBIT $-18.80m
Free Cash Flow (TTM) Free Cash Flow $-5.54m
EPS (TTM) EPS $-6.66
P/E forward negative
Short interest 2.08%
Show more

Is Kazia Therapeutics Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Kazia Therapeutics Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Kazia Therapeutics Ltd Sponsored ADR:

Buy
100%

Financial data from Kazia Therapeutics Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
1.52 1.52
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.68 7.68
70% 70%
505%
- Research and Development Expense 10 10
11% 11%
670%
-18 -18
17% 17%
-1,156%
- Depreciation and Amortization 1.22 1.22
3% 3%
80%
EBIT (Operating Income) EBIT -19 -19
16% 16%
-1,237%
Net Profit -18 -18
28% 28%
-1,156%

In millions USD.

Don't miss a Thing! We will send you all news about Kazia Therapeutics Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Kazia Therapeutics Ltd Sponsored ADR Stock News

Neutral
PRNewsWire
4 days ago
Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY , March 31, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or "the Company"), an oncology-focused drug development company, today announced the sale of all intellectual property and trademarks rights to Cantrixil for USD...
Neutral
PRNewsWire
2 months ago
SYDNEY , Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical trial evaluating the combination of paxalisib and immunotherapy in patients with advanced breast cancer. This novel treatment combination offers what is believed to be a unique approach to targeting...
Neutral
PRNewsWire
3 months ago
SYDNEY , Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previously announced registered direct offering with existing fundamental healthcare investor, Alumni Capital LP, of 1,333,333 of the Company's American Depositary Shares ("ADSs") (or ADS equivalents in ...
More Kazia Therapeutics Ltd Sponsored ADR News

Company Profile

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Head office Australia
CEO John Friend
Founded 1994
Website www.kaziatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today